Nutriband inc. quarterly report highlights strong cash position, and strategic progress toward nda filing for aversa fentanyl in 2025

Orlando, fl / accesswire / september 4, 2024 / nutriband inc. (nasdaq:ntrb)(nasdaq:ntrbw) has reported its financial results for the second quarter ended july 31, 2024. the company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, aversa™ fentanyl, with an nda submission targeted for the first half of 2025.
NTRB Ratings Summary
NTRB Quant Ranking